Abstracts

RISK AND PREVALENCE OF RESIDUAL VIREMIA AFTER CART IN RESOURCE-LIMITED COUNTRIES

Tuberculosis, hepatitis B and C, sexually transmitted and tropical infections may contribute to higher residual viremia in virally suppressed people with HIV (PWH). The limited data describe residual viremia from low- and middle-income countries (LMIC). We assessed the prevalence, and factors associated with residual viremia in PWH, who were virally-suppressed on combination antiretroviral therapy (cART).…

PROVIRAL/HUMAN GENOMIC CROSSTALK IN CELLULAR MODELS FOR HIV INFECTION

Chronic HIV-1 infection is characterized by accumulation of proviral sequences in the genome of HIV target cells. Integration of viral-derived DNA is found at preferential loci, suggesting site-specific crosstalk between viral sequences and human genes. This crosstalk has been postulated to play a role in emergence of clonal infected cell populations. The molecular nature of…

EPIGENOMIC CHARACTERIZATION OF A PRIMARY CELL MODEL OF HIV LATENCY

Transcriptional silencing of HIV in CD4 T cells generates a reservoir of latently infected cells that can reseed infection after interruption of therapy.  As such, these cells represent the principal barrier to curing HIV infection, but little is known about the characteristics or regulation of the latent reservoir.   To further our understanding of the molecular mechanisms…

SINGLE-CELL ANALYSIS SHOWS MOLECULAR SIGNATURES OF HIV LATENCY IN PRIMARY CELL MODELS

Primary cell models have greatly advanced our understanding of HIV latency. However, it is unclear what mechanisms underlie latency in these primary cell models. We hypothesized that molecular signatures can distinguish uninfected, latently- and productively-infected populations in these models. We assessed 4 primary cell models [blood CD4T cells: models from labs of Eric Verdin, Alberto…

NEAR NORMALIZATION OF IMMUNE ACTIVATION IN PLWH ON LONG-TERM SUPPRESSIVE ART

In HIV-infected patients, chronic immune activation and inflammation persist after suppressive combination antiretroviral therapy (cART). We compared gene expression and biomarkers in peripheral blood between HIV-infected patients on long-term suppressive cART (HIV-group) and age-matched healthy controls (HC-group). Cross-sectional study of 22 subjects in HIV-group with HIV-RNA <50 copies/ml and CD4+ T-cells ≥500 cells/mm3 for more…

EXPRESSION PROFILING OF HIV LATENTLY INFECTED CELLS VIA NANOSTRING AND MASS CYTOMETRY

The main barrier to an HIV cure is the latent HIV reservoir. Long-lived HIV latently-infected cells remain invisible to the host immune system and persist during antiretroviral therapy. In this study, we characterized latently-infected cells by implementing combined transcriptomic and proteomic profiling to identify unique expression signatures and reliable biomarkers that can be exploited to…